403 results on '"Pallisgaard, Niels"'
Search Results
2. Circulating tumour DNA and its clinical utility in predicting treatment response or survival in patients with metastatic colorectal cancer: a systematic review and meta-analysis
3. Perioperative changes in cell-free DNA for patients undergoing surgery for colon cancer
4. Figure S2 from Liquid Biopsies with Circulating Plasma HPV–DNA Measurements—A Clinically Applicable Surveillance Tool for Patients with HPV-Positive Oropharyngeal Cancer
5. Supplementary appendix S2 from Liquid Biopsies with Circulating Plasma HPV–DNA Measurements—A Clinically Applicable Surveillance Tool for Patients with HPV-Positive Oropharyngeal Cancer
6. Data from Liquid Biopsies with Circulating Plasma HPV–DNA Measurements—A Clinically Applicable Surveillance Tool for Patients with HPV-Positive Oropharyngeal Cancer
7. Figure S1A and S1B from Liquid Biopsies with Circulating Plasma HPV–DNA Measurements—A Clinically Applicable Surveillance Tool for Patients with HPV-Positive Oropharyngeal Cancer
8. ctDNA-guided adjuvant treatment after radical-intent treatment of metastatic spread from colorectal cancer—the first interim results from the OPTIMISE study
9. Safety and Efficacy of Doxorubicin, Cyclophosphamide, Bortezomib, Dexamethasone and Lenalidomide Followed by Bortezomib Consolidation as First-Line Therapy in Patients with Newly Diagnosed Multiple Myeloma
10. Evidence of immune elimination, immuno-editing and immune escape in patients with hematological cancer
11. Prevalence and phenotypes of JAK2 V617F and calreticulin mutations in a Danish general population
12. Liquid Biopsies with Circulating Plasma HPV–DNA Measurements—A Clinically Applicable Surveillance Tool for Patients with HPV-Positive Oropharyngeal Cancer
13. International external quality assurance of JAK2 V617F quantification
14. A comparison of qPCR and ddPCR used for quantification of the JAK2 V617F allele burden in Ph negative MPNs
15. Data from Circulating Tumor DNA Monitoring Reveals Molecular Progression before Radiologic Progression in a Real-life Cohort of Patients with Advanced Non–small Cell Lung Cancer
16. Supplementary Figure FS7 from Circulating Tumor DNA Monitoring Reveals Molecular Progression before Radiologic Progression in a Real-life Cohort of Patients with Advanced Non–small Cell Lung Cancer
17. Supplementary Table TS3 from Circulating Tumor DNA Monitoring Reveals Molecular Progression before Radiologic Progression in a Real-life Cohort of Patients with Advanced Non–small Cell Lung Cancer
18. Table 5 from Quantitative Cell-Free DNA, KRAS, and BRAF Mutations in Plasma from Patients with Metastatic Colorectal Cancer during Treatment with Cetuximab and Irinotecan
19. Figure 4 from Quantitative Cell-Free DNA, KRAS, and BRAF Mutations in Plasma from Patients with Metastatic Colorectal Cancer during Treatment with Cetuximab and Irinotecan
20. Figure 3 from Quantitative Cell-Free DNA, KRAS, and BRAF Mutations in Plasma from Patients with Metastatic Colorectal Cancer during Treatment with Cetuximab and Irinotecan
21. Table 6 from Quantitative Cell-Free DNA, KRAS, and BRAF Mutations in Plasma from Patients with Metastatic Colorectal Cancer during Treatment with Cetuximab and Irinotecan
22. Figure 5 from Quantitative Cell-Free DNA, KRAS, and BRAF Mutations in Plasma from Patients with Metastatic Colorectal Cancer during Treatment with Cetuximab and Irinotecan
23. CPP1, a DNA-Binding Protein Involved in the Expression of a Soybean Leghemoglobin c3 Gene
24. Endoscopic Calcium Electroporation for Colorectal Cancer: a phase I study
25. High frequencies of circulating memory T cells specific for calreticulin exon 9 mutations in healthy individuals
26. Circulating Tumor DNA Monitoring Reveals Molecular Progression before Radiologic Progression in a Real-life Cohort of Patients with Advanced Non–small Cell Lung Cancer
27. OPTIMISE: Optimisation of treatment selection and follow-up in oligometastatic colorectal cancer – a ctDNA-guided phase II randomised approach. Study protocol
28. Copy number alterations define outcome in Philadelphia chromosome-positive acute lymphoblastic leukemia
29. Copy number alterations define outcome in Philadelphia chromosome-positive acute lymphoblastic leukemia
30. Total cell‑free DNA measurement in metastatic colorectal cancer with a fast and easy direct fluorescent assay
31. Dansk Database for Kroniske Myeloproliferative Neoplasier:Årsrapport 2020
32. Identification of Trans-Acting Factors Regulating Nodulin Gene Expression
33. Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery
34. Molecular diagnostics of myeloproliferative neoplasms
35. Assessment of droplet digital polymerase chain reaction for measuring BCR‐ABL1 in chronic myeloid leukaemia in an international interlaboratory study
36. Clinicopathological factors associated with tumour-specific mutation detection in plasma of patients with RAS-mutated or BRAF-mutated metastatic colorectal cancer
37. Cell-free DNA in healthy individuals, noncancerous disease and strong prognostic value in colorectal cancer
38. Changes in mutational status during third-line treatment for metastatic colorectal cancer—Results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasma
39. Plasma HER2 amplification in cell-free DNA during neoadjuvant chemotherapy in breast cancer
40. Clinicopathological factors associated with tumour‐specific mutation detection in plasma of patients withRAS‐mutated orBRAF‐mutated metastatic colorectal cancer
41. The Clinical Value of Measuring Circulating HPV DNA during Chemo-Radiotherapy in Squamous Cell Carcinoma of the Anus
42. A 3-weekly schedule of irinotecan and panitumumab for wild-type KRAS metastatic colorectal cancer
43. Correlation between circulating cell‐free PIK3CA tumor DNA levels and treatment response in patients with PIK3CA‐mutated metastatic breast cancer
44. A der(18)t(9;18)(p13;p11) and a der(9;18)(p10;q10) in polycythemia vera associated with a hyperproliferative phenotype in transformation to postpolycythemic myelofibrosis
45. Digital PCR for BCR-ABL1 Quantification in CML: Current Applications in Clinical Practice
46. Contribution of multiparameter genetic analysis to the detection of genetic alterations in hematologic neoplasia. An evaluation of combining G-band analysis, spectral karyotyping, and multiplex reverse-transcription polymerase chain reaction (multiplex RT-PCR)
47. A new class of plant homeobox genes is expressed in specific regions of determinate symbiotic root nodules
48. Circulating tumor DNA as a marker of minimal residual disease following local treatment of metastases from colorectal cancer
49. Ruxolitinib and interferon-α2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study
50. Data‐driven analysis of JAK2V617F kinetics during interferon‐alpha2 treatment of patients with polycythemia vera and related neoplasms
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.